Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP1 | O94782 | 4/20 | 1.00 |
| ▸ | USP19 | O94966 | 2/20 | 1.00 |
| ▸ | WDR48 | Q8TAF3 | 1/20 | 1.00 |
| ▸ | UCHL3 | P15374 | 1/20 | 0.77 |
| ▸ | USP2 | O75604 | 2/20 | 0.73 |
| ▸ | USP8 | P40818 | 2/20 | 0.73 |
| ▸ | OTUB1 | Q96FW1 | 2/20 | 0.73 |
| ▸ | USP36 | Q9P275 | 1/20 | 0.73 |
| ▸ | ELANE | P08246 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | AHR | P35869 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29629183 | 1.00 | USP1 (1.00) | USP1USP19WDR48UCHL3USP2 | |
| SCHEMBL29629184 | 1.00 | USP1 (1.00) | USP1USP19WDR48UCHL3USP2 | |
| SCHEMBL19220486 | 0.90 | USP1 (0.82) | USP1USP19WDR48UCHL3USP2 | |
| SCHEMBL18347790 | 0.88 | USP1 (0.79) | USP1USP19WDR48UCHL3USP2 | |
| SCHEMBL18203587 | 0.88 | USP1 (0.79) | USP1USP19WDR48UCHL3USP2 | |
| SCHEMBL7968066 | 0.87 | USP1 (0.77) | USP1USP19WDR48UCHL3USP2 | |
| SCHEMBL7815859 | 0.87 | USP1 (1.00) | USP1USP19WDR48UCHL3USP2 | |
| SCHEMBL7808410 | 0.87 | USP1 (0.77) | USP1USP19WDR48UCHL3USP2 | |
| SCHEMBL31276578 | 0.87 | USP1 (1.00) | USP1USP19WDR48UCHL3USP2 | |
| SCHEMBL19225117 | 0.87 | USP1 (0.77) | USP1USP19WDR48UCHL3USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210186964-A1 | METHODS OF TREATING CANCERS | DANA-FARBER CANCER INSTITUTE, INC. | 2021-06-24 | — | — | US | disclosed |
| US-10450281-B1 | Compounds and methods for treating cancer | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| US-10450281-B1 | Compounds and methods for treating cancer | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| US-9725425-B1 | Compounds and methods for treating cancer | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-9725425-B1 | Compounds and methods for treating cancer | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-9725425-B1 | Compounds and methods for treating cancer | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| EP-0876356-B1 | USE OF TRICYCLIC 1,4-DIHYDRO-1,4-DIOXO-1H-NAPHTHALENE DERIVATIVES, RESULTING NOVEL COMPOUNDS AND THERAPEUTICAL USE THEREOF | INNOTHERA SA LAB (FR) | 2001-10-31 | — | — | EP | disclosed |
| US-6262095-B1 | TREATMENT OF ILLNESS ASSOCIATED WITH AN ALTERATION IN VENOUS FUNCTION AND/OR INFLAMMATORY EDEMA | LABORATOIRE INNOTHERA (FR) | 2001-07-17 | — | — | US | disclosed |
| EP-0876356-A1 | USE OF TRICYCLIC 1,4-DIHYDRO-1,4-DIOXO-1H-NAPHTHALENE DERIVATIVES, RESULTING NOVEL COMPOUNDS AND THERAPEUTICAL USE THEREOF | LABORATOIRE INNOTHERA Société Anonyme (FR) | 1998-11-11 | — | — | EP | disclosed |
| WO-1997021684-A1 | USE OF TRICYCLIC 1,4-DIHYDRO-1,4-DIOXO-1H-NAPHTHALENE DERIVATIVES, RESULTING NOVEL COMPOUNDS AND THERAPEUTICAL USE THEREOF | LABORATOIRE INNOTHERA, SOCIETE ANONYME (FR) | 1997-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210186964-A1 | METHODS OF TREATING CANCERS | BRCA1, TP53, BAP1 | USP1 6/4885USP19 89/4885WDR48 908/4885 |
| US-10450281-B1 | Compounds and methods for treating cancer | USP8, USP2, NEDD8 | USP1 7/4885USP19 22/4885WDR48 306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.